Targeting an Essential GTPase Obg for the Development of Broad-Spectrum Antibiotics

Josephine A. Bonventre1, Ryszard A. Zielke1, Konstantin V. Korotkov2, Aleksandra E. Sikora1*

1 Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, OR, 97330, United States of America, 2 Department of Molecular and Cellular Biochemistry, and Center for Structural Biology, University of Kentucky, Lexington, KY, 40536, United States of America

* Aleksandra.Sikora@oregonstate.edu

Abstract

A promising new drug target for the development of novel broad-spectrum antibiotics is the highly conserved small GTPase Obg (YhbZ, CgtA), a protein essential for the survival of all bacteria including Neisseria gonorrhoeae (GC). GC is the agent of gonorrhea, a prevalent sexually transmitted disease resulting in serious consequences on reproductive and neonatal health. A preventive anti-gonorrhea vaccine does not exist, and options for effective antibiotic treatments are increasingly limited. To address the dire need for alternative antimicrobial strategies, we have designed and optimized a 384-well GTPase assay to identify inhibitors of Obg using as a model Obg protein from GC, ObgGC. The assay was validated with a pilot screen of 40,000 compounds and achieved an average Z’ value of 0.58 ± 0.02, which suggests a robust assay amenable to high-throughput screening. We developed secondary assessments for identified lead compounds that utilize the interaction between ObgGC and fluorescent guanine nucleotide analogs, mant-GTP and mant-GDP, and an ObgGC variant with multiple alterations in the G-domains that prevent nucleotide binding. To evaluate the broad-spectrum potential of ObgGC inhibitors, Obg proteins of Klebsiella pneumoniae and methicillin-resistant Staphylococcus aureus (MRSA) were assessed using the colorimetric and fluorescence-based activity assays. These approaches can be useful in identifying broad-spectrum Obg inhibitors and advancing the therapeutic battle against multidrug resistant bacteria.

Introduction

Antibiotic resistance is a natural phenomenon made more precipitous by the misuse of antimicrobial drugs, which has accelerated the appearance of drug-resistant bacteria (reviewed in: [1]). It is estimated that over two million people are diagnosed with antibiotic resistant illnesses in the United States alone each year, and that greater than 300 million cumulative premature deaths will result worldwide by 2050 [2]. Antibiotic resistant infections, such as those caused by Clostridium difficile, carbapenem-resistant Enterobacteriaceae, particularly Klebsiella species, and methicillin-resistant Staphylococcus aureus (MRSA), result in prolonged illness, with...
potentially greater mortality and morbidity, and added healthcare expenditure [3, 4]. Contributing to the complications of increased multi-drug resistance is the relative lack of novel antibiotics introduced to market [1, 4, 5]. The drought of new discoveries in the field is due in large part to the absence of many Big Pharma research and development programs in this area [6, 7]. Drug discovery remains an expensive and time-consuming endeavor, costing pharmaceutical companies millions of dollars to bring a compound from bench to market, and often these chemicals fail before entering clinical trials [7–9]. In addition, an effective antibiotic ideally cures an infection in a few doses, which makes the financial investment into the drug discovery process not as profitable as medication for chronic illnesses. Nevertheless, there is a pressing need to address the global antibiotic resistance health crisis, and the task of developing screening programs for novel drug targets now primarily rests on the shoulders of academia and small pharmaceutical companies [2, 4].

Investigating target molecules for the development of broad-spectrum antibiotics against drug-resistant bacterial infections is often more cost effective than developing a compound with activity against a single pathogen because of the wider clinical applications. As a result, biological targets that are essential to the physiology of the microorganism and conserved across various species are traditionally preferential drug candidates [6]. For example, inhibiting DNA replication, the ribosome function, or cell-wall biosynthesis has proven to be viable strategies [9, 10].

We have recently proposed the Obg protein (YhbZ, CgtA) as a molecular target for development of new therapeutic interventions against drug-resistant bacteria [11]. Obg and Obg-like proteins are highly conserved GTPases, present in bacteria, archaea, and eukaryota [12–15]. The bacterial Obg proteins have a unique structure (S1 Fig) containing highly conserved glycine-rich N-terminal domain, conserved GTP-binding domain, and a variable C-terminal domain [11, 12, 16, 17]. Few Obg proteins have been crystalized to date [16, 18], however, the N-terminus has thus far demonstrated the most favorable potential for protein-protein interactions [19–21].

G proteins typically display high affinities for nucleotides, low dissociation rates in the absence of exogenous exchange factors, and low intrinsic hydrolysis activity. In many eukaryotic Ras-like GTPases these properties are regulated by guanine exchange factors (GEFs), GTPase activating proteins (GAPs), and guanidine dissociation inhibitors (GDIs) [22]. Detailed biochemical analysis demonstrated, however, that Obg GTPases are clearly distinct. They display slow rate of GTP hydrolysis, micromolar binding constants for GTP and GDP, and rapid dissociation constants for either GTP or GDP, which are $10^3$–$10^5$ faster than that of Ras-like GTPases. These biochemical features of Obg, if considered in the absence of potential GEFs, GAPs, and GDIs, suggest that Obg proteins act as intracellular sensors and their nucleotide-bound state is controlled by relative GTP/GDP concentration [12].

Obg homologs are essential for the survival of both Gram-positive and Gram-negative bacteria, including Bacillus subtilis, Streptomyces coelicolor, Staphylococcus pneumoniae, S. aureus, Haemophilus influenzae, Caulobacter crescentus, Escherichia coli, Vibrio harveyi, V. cholerae, and Neisseria gonorrhoeae, with depletion of the protein resulting in species-specific pleiotropy [11, 23–29]. Bacterial Obg proteins have been associated with a variety of cellular functions, including ribosome biogenesis and maturation, DNA synthesis and replication, chromosomal segregation, regulation of the cell stress response, and recently, persistence in response to nutrient starvation [12, 13, 30]. Obg proteins bind not only GTP and GDP, but also the alarmone nucleotide, (p)ppGpp, which implies a role for this protein in the stringent response [11, 28, 31, 32]. Specifically, Obg-mediated persistence in E. coli and Pseudomonas aeruginosa requires (p)ppGpp, suggesting Obg may have a critical function in the failure of some antibiotic treatments [30].
Both the association between Obg and ribosome assembly and its proposed role in inducing bacterial multidrug tolerance make Obg a promising drug target [10, 11, 33]. To that end, our laboratory has targeted *N. gonorrhoeae* (gonococcus, GC) Obg, ObgGC, as a model protein for screening and identifying potential broad-spectrum inhibitors of Obg GTPase activity. GC, a Gram-negative bacterium, human-specific pathogen, and the etiological agent of gonorrhea, is listed among top three urgent antibiotic resistant threats according to the Centers for Disease Control and Prevention [34]. The sexually transmitted infection (STI) is a global health burden with 78 million of the estimated 498 million new cases of curable STIs that occur worldwide every year [35]. The disease causes cervicitis, urethritis, proctitis, conjunctivitis, or pharyngitis, and left untreated, leads to long-term health consequences including endometriosis, pelvic inflammatory disease, and infertility [36, 37]. At the turn of the 20th century, GC infections were treated with penicillin, but over time, GC has acquired resistance to nearly all antimicrobials used in the clinic (reviewed in: [38, 39]). Currently, a vaccine for gonorrhea does not exist, and options for effective antibiotics are increasingly limited. Third-generation cephalosporin antibiotic regimens remain the final line of defense as multi-drug resistant GC isolates continue to be identified across the globe, threatening future treatment options [36, 38–41].

To address the dire need for alternative antimicrobial strategies against drug-resistant infections including gonorrhea, we developed an end-point ObgGC-GTP hydrolysis assay using the malachite green-based detection of the free phosphate as a read out. The assay was optimized and conducted in 384-well plates with a pilot screen of 40,000 small molecules. The Z’ values calculated from our initial screen of small molecules averaged 0.58 ± 0.02 over the course of five weeks, suggesting a robust, sensitive assay amenable to high-throughput screening (HTS). In addition, to eliminate nonspecific inhibitors and elucidate potential mechanism(s) of inhibition for lead compounds, we propose secondary Obg activity assessment methods based on the binding of fluorescent N-methyl-3′-O-anthranoyl-(mant)-guanine nucleotide analogs, mant-GTP and mant-GDP. A variant of ObgGC with multiple alterations in the G-domains that is unable to bind both mant-GTP and mant-GDP was designed to serve as a positive control in the secondary assays. Finally, to test the broad-spectrum potential of ObgGC inhibitors, the recombinant versions of Obg proteins from *Klebsiella pneumoniae* (ObgKP) and MRSA (ObgMRSA) were cloned, purified, and assessed using colorimetric and fluorescence-based activity experiments.

In summary, we report a strategy for targeting a pivotal GTPase Obg that can be used to identify and optimize broad-spectrum chemical inhibitors for the treatment of gonorrhea and other diseases caused by multidrug resistant bacteria.

**Materials and Methods**

**Bacterial strains, plasmids, and growth conditions**

The *E. coli* strains NEB5α and BL21(DE3) were used for genetic manipulations and protein overproduction, respectively. Bacteria were streaked from glycerol stocks stored at -80°C on Luria-Bertani (LB) agar supplemented with kanamycin (50 μg/mL) when needed. *E. coli* strains were cultured in LB medium at 37°C. Culture media utilized in this study were purchased from Difco.

**Construction of recombinant wild type and mutated version of ObgGC**

Genomic DNA was isolated from GC FA1090, a clinical isolate (1–007) of *K. pneumoniae* and MRSA (ATCC 25923) using Wizard Genomic DNA Purification Kit (Promega, Madison, WI). Construction of recombinant wild type ObgGC containing C-terminally attached 6×His-tag, His-ObgGC, was described previously [11]. To generate *ObgGC*, a DNA fragment containing
obg gene from GC FA1090 (NGO1990) with designed mutated sites within G domains T192S, T193S, A212L, D213E, P215H, N284Q, K285R, S329V and 6×His-tag was synthesized as gBlock Gene Fragment by Integrated DNA Technologies (IDT DNA, Coralville, IA). The gBlock fragment was cut with XbaI and HindIII and cloned into similarly digested pET-ObgGC [11] to yield pET-’ObgGC. The presence of the desired mutations was confirmed by DNA sequencing at Center for Genome Research and Biocomputing at Oregon State University.

To create C-terminal 6×His fusion of obg from MRSA, the obg gene was amplified using primers obg (MRSA)-f (GATCCCATGGTTGTCGATCAAGTCAAAATATC) and obg (MRSA)-r (GACTAAGCTTCGCTCCTATTCAACGAATT). The resulting PCR product was digested with NcoI and HindIII and cloned into similarly treated pET-28a to create pET-ObgMRSA.

To create plasmid pKV1414 bearing ObgKP, the DNA fragment corresponding to residues 1–392 was PCR-amplified from K. pneumoniae genomic DNA using primers Obg_kpn_F1Nde (GAGACATATGAAGTTTGTAGATGAAGCAAC) and Obg_kpn_R392Hind (CTCAAGCTTAGCTTGAGATGAATTCG), digested with NdeI and HindIII, and cloned into a modified pCDF-Duet1 vector (Novagen/Merck KGaA, Darmstadt, Germany), to append an N-terminal 6×His tag and a tobacco etch virus (TEV) protease cleavage sequence.

**Purification of *ObgGC, ObgKP and ObgMRSA**

All recombinant proteins were expressed using the *E. coli* BL21(DE3) as a host and purified as follows. Bacteria harboring pET-OBG GC, pET-’ObgGC, pKV1414, or pET-ObgMRSA were cultured in LB supplemented with kanamycin at 37°C until the cultures reached OD600 of ~ 0.5, and the gene expression was induced by the addition of isopropyl-β-D-thiogalactoside (IPTG) to a final concentration of 1 mM. Cells were pelleted 3 h after induction and resuspended in lysis buffer (20 mM Tris–HCl pH 8.0, 10 mM imidazole, 500 mM NaCl). The cells were lysed by passing the suspension four times through a French pressure cell press at 12,000 psi. Bacterial debris was removed by centrifugation and filtered through 0.45 μm filter (VWR, Radnor, PA). Cell lysates were applied on 5 mL Bio-Scale™ Mini Profinity™ IMAC Cartridges (Bio-Rad, Hercules, CA) connected to NGC Chromatography System (Bio-Rad, Hercules, CA) equilibrated with 5 column volumes of lysis buffer. Column was washed with 8 column volumes of lysis buffer and bound protein was eluted with buffer containing 20 mM Tris–HCl pH 8.0, 250 mM imidazole, and 500 mM NaCl. Fractions containing Obg were pooled and concentrated using Vivaspin 20 (MWCO 10,000) spin concentrators (GE Healthcare Bio-Sciences, Pittsburgh, PA). Concentrated fractions were applied on HiLoad 16/600 Superdex 75 column (GE Healthcare Bio-Sciences, Pittsburgh, PA) and resolved using buffer containing 20 mM Tris pH 8 and 100 mM NaCl. Subsequently, samples containing the respective Obg variants were pooled and concentrated using Vivaspin 6 (MWCO 10,000) spin concentrators (GE Healthcare Bio-Sciences, Pittsburgh, PA).

Protein concentrations were determined using the Bradford method with a Protein Assay Kit (Bio-Rad, Hercules, CA). Glycerol was added to purified proteins to a final concentration of 10% and proteins were stored at -80°C.

**Assay optimization**

A colorimetric GTPase assay was developed to screen for Obg inhibitors. The assay was based on the molybdate/malachite green detection method [42] and measures free phosphate in the solution following the addition of the BIOMOL® Green reagent (Enzo Life Sciences, Farmingdale, NY). The reaction was optimized for ObgGC and GTP concentration in buffer A.
containing 50 mM Tris pH 8.0, 2 mM dithiothreitol, 1 mM ethylenediaminetetraacetic acid (EDTA), 50 mM KCl, 10% (wt/vol) glycerol and 10 mM MgCl₂.

First, the optimal protein concentration for the assay was evaluated using 1, 2, 5, or 10 μM ObgGC and 125 μM GTP with incubation time of 6 h at 37°C. Next, 5 μM ObgGC was incubated with 125, 250, 500, 750 or 1000 μM GTP. At the end of each incubation period, BIOMOL Green was added at twice the volume of the reaction to quench it, and samples were allowed to incubate for 30 min at room temperature. The colorimetric measurements were performed at 620 nm using the BioTek Synergy HT Multi-Detection Microplate Reader (BioTek, Shoreline, WA). Absorbance values were related to the amount of phosphate released during Obg-mediated GTP hydrolysis. Ultimately, 5 μM ObgGC and 250 μM GTP were selected, and a time-course was performed to measure phosphate release over time. The Km for ObgGC was determined using 10, 25, 50, 100, 250, 500, 1000 μM GTP during a 6 h period.

To determine the optimal incubation length and temperature to be used for the primary screen of compound libraries, nine identically loaded 384-well plates with 25 μl reactions were incubated under three conditions: 6 h at 37°C, 18 h at 37°C, and 18 h at room temperature (3 plates each). In addition to the wells with complete reaction mixture (RM) containing 5 μM ObgGC, 250 μM GTP in buffer A (columns 2–22), each plate accommodated a background control comprising of RM lacking ObgGC (column 1) and a positive control (RM without MgCl₂; columns 23–24). The amount of free phosphate present under each condition was measured using BIOMOL Green as described above, and the difference between high-activity wells and low-activity wells was evaluated. Incubation for 18 h at 37°C was ultimately selected for future studies.

ObgGC activity was tested for solvent tolerance and sensitivity to chelators. ObgGC was incubated with various concentrations of dimethyl sulfoxide (DMSO), 0, 0.5, 1, 2, 3, 4, and 5%, in RM on 384 well plates as outlined above to determine if DMSO interferes with Obg-mediated GTP hydrolysis. The assay was incubated and the amount of free phosphate was measured as described above. The effect of compounds that may act as Mg²⁺ chelators and disrupt or inhibit the ObgGC GTPase activity was tested using common chelators including EDTA (Amresco, Solon, OH), ethylene glycol tetra acetic acid (EGTA; Alfa Aesar, Ward Hill, MA), Nitrilotriacetic acid (NTA; TCI, Portland, OR), and citric acid (CA; Sigma Aldrich, St. Louis, MO) at the test-compound concentration used in HTS (40 μM). The protein was pre-incubated with each chelator for 1 h prior to the addition of GTP, and the assay was completed as described above.

**Primary screen**

For the HTS, reagents were added to 384-well microplates using a BioTek MultiFlo Dispenser (BioTek, Shoreline, WA), and plates were delivered to the Oregon Translational Research and Drug Development Institute (OTRADI) satellite lab at Oregon State University for compound loading. Daughter plates were made from stock mother plates from the SIGA chemical library [7] in 10% DMSO, such that the final concentrations of the compounds and DMSO in the screening reaction were 40 μM and 0.8% (v/v), respectively. Each plate contained RM without ObgGC (column 1), negative control comprising of RM and no compounds (column 2), and two columns of a positive control (RM without MgCl₂, column 23–24).

Following compound addition (columns 3–22), 5 μM Obg was loaded into the wells, and the protein was allowed to incubate with compounds for 1 h at room temperature, prior to the addition of GTP (250 μM). The amount of released phosphate was measured following incubation as described above. The percent activity of each compound was calculated from the absorbance data using the following equation:

\[
\% \text{ Activity} = \left( \frac{C_{Pc}}{Nc_{Pc}} \right) \times 100 \quad \text{Eq (1)}
\]
where \( C \) is the absorbance recorded for each reaction containing individual compounds and \( \text{Obg}_{GC} \), \( P_c \) is the average of all positive controls, and \( N_c \) is the average of all negative controls.

To confirm the inhibitory effect on GTPase activity of Obg, compounds resulting in 15% or more reduction in activity were selected for repeat screening with the BIOMOL Green assay in triplicate. Subsequently, compounds demonstrating 50% \( \text{Obg}_{GC} \) inhibition were selected for follow-up dose-dependence studies.

Three compounds selected for further testing included: Compound A: 2-chloro-4-nitro-6-\{[(E)-2-nitroethenyl]amino\}phenol (ChemBridge, San Diego, CA), Compound B: 9-(4-nitrophenyl)-5,13-disulfanyl-2-oxa-4,6,12,14-tetraazatricyclo[8.4.0.0³,⁸]tetradeca-1(10),3,5,7,11,13-hexaene-7,11-diol (Vitas-M Lab Ltd, Moscow, Russia), and bacterial GTPase EngA inhibitor, Garcinol (Enzo Life Sciences, Farmingdale, NY), identified in a previous HTS [43]. \( \text{Obg}_{GC} \) was incubated with 40 or 100 \( \mu \)M of the chemical for 1 h in RM prior to addition of GTP, followed by measurement of free phosphate amounts as described above.

**Secondary screen**

N-methyl-3'-O-anthranoyl-(mant)-guanine nucleotide analogs of GTP and GDP (mant-GTP and mant-GDP, respectively) were purchased from Thermo Fisher Scientific (Waltham, MA). Protein (\( \text{Obg}_{GC} \) or \( \text{Obg}_{MRSA} \), 2 \( \mu \)M) was incubated with either mant-GTP or mant-GDP nucleotide (0.3 \( \mu \)M) in buffer containing 50 mM Tris, 2 mM DTT, 1 mM EDTA, 50 mM KCl, 10% (wt/vol) glycerol, and for reactions with mant-GTP, 5 mM MgCl\(_2\) was included [11]. All fluorescence measurements were performed at 37°C using a Synergy HT plate reader (BioTek, Shoreline, WA). These studies were carried out at least eight times over multiple days. The means for the biological replicates with corresponding standard error of the mean (SEM) are reported.

**Assessment of the potential broad-spectrum activity of lead compounds**

The activity of \( \text{Obg}_{KP} \) and \( \text{Obg}_{MRSA} \) was determined in the colorimetric and fluorescent assays as described for \( \text{Obg}_{GC} \). In addition, the GTP hydrolysis rate of both proteins (16 \( \mu \)M) was determined by recording the decrease in fluorescence of mant-GTP (0.3 \( \mu \)M) at 1 min intervals for 3 h [11]. Data were fitted to a single exponential decay equation, and the single turnover rate constant and the half-life of hydrolysis were calculated.

**Statistical analyses**

Statistical analyses were conducted using GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA). Unpaired t-test or One-way Analysis of Variance (ANOVA) with post hoc tests were used to determine differences in free phosphate detection or changes in fluorescence where appropriate (\( P \leq 0.01 \)). The primary screen was evaluated using statistical parameters of signal to noise (S:N), signal to background (S:B), signal window (SW), \( Z' \) factor, and inter/intraplate variability (%CV), which were calculated as previously described [44, 45].

**Results and Discussion**

Targeting ribosome function and biogenesis has led to some of the most clinically effective antibiotics currently in use, including tetracyclines and aminoglycosides [10, 33]. The association between Obg and the bacterial ribosome, specifically with the 50S subunit, has been well documented (reviewed in: [12]). In addition to its role in ribosomal maturation, alterations of many other critical cellular processes have also been attributed to the loss of Obg function, including DNA synthesis and replication, chromosomal segregation, regulation of the cell
stress response, and bacterial persistence [11, 23–30]. The pivotal function(s) of Obg in key physiological processes make Obg a promising target for the development of novel antibiotics. Here we optimized conditions for HTS of small molecule inhibitors using as a model system ObgGC from N. gonorrhoeae, a clinically important bacterium rapidly acquiring antibiotic resistance and causing multi-drug resistant infections that call for alternative antimicrobial interventions.

**Rationale and assay optimization**

To develop an assay for screening of Obg inhibitors, we targeted the GTPase Obg activity because it is critical for Obg function *in vivo* and bacterial viability [46]. Measuring released phosphate as a result of Obg GTP hydrolysis also provides a technically feasible endpoint. The BIOMOL® Green assay is a commercial version of a common phosphate detection assay originally established based on the principle that malachite green complexed with phosphomolybdate leads to a shift in λ<sub>max</sub> [42]. A similar methodology was recently used in a HTS designed for a ribosome-associated bacterial GTPase, EngA, resulting in four prospective inhibitors [43]. One of the four, Garcinol, was available for purchase and tested for its ability to inhibit the ObgGC activity (S2A Fig), emphasizing the need to establish a new screening campaign to target the GTPase Obg.

An alternative means of measuring Obg activity is via fluorescent N-methyl-3'-O-anthranoyl guanine nucleotide analogs of GTP and GDP. Mant-GTP and mant-GDP have been widely utilized for examining the nucleotide binding and GTP hydrolysis of various G-proteins, including Obg homologs from *C. crescentus* [31], *E. coli* [47], *V. harveyi* [48], and recently *N. gonorrhoeae* [11]. When bound to proteins, fluorescence increases by ~2- and 1.3-fold for mant-GTP and mant-GDP, respectively. However, despite the sensitivity of the fluorescent assay, the minimal fold induction does not provide a substantial window for HTS [44, 45]. Therefore, we proceeded with optimizing the BIOMOL Green assay for efficiency and high-throughput competency.

The initial conditions used to optimize the assay, the protein and GTP concentrations as well as incubation time, were chosen with the knowledge that ObgGC hydrolyzes GTP approximately twenty times slower than the *V. harveyi* Obg and two-fold slower than that of *C. crescentus* Obg, and slightly slower than *E. coli* Obg protein, with a half-life of GTP of approximately 50 min [11]. Preliminary studies using the BIOMOL Green assay revealed that at least 6 h of incubation were required to provide a significant fold change above background (data not shown). We therefore began optimization studies with a 6 h incubation length to accommodate for the slow GTP hydrolysis time. In contrast, incubation time for the EngA GTPase HTS was only 25 min [43]. When ObgGC was incubated with 125 μM GTP for 6 h at 37°C, the amount of phosphate detected in the presence of 5 and 10 μM ObgGC showed a marginal difference, 72 versus 75 μM, and therefore 5 μM was selected to obtain a more favorable protein to compound ratio in the screen (Fig 1A). Incubation of 5 μM ObgGC with 125–1000 μM GTP, showed a linear dependence on substrate concentration up to 250 μM, and it was therefore selected as the GTP concentration for the screen (Fig 1B).

While the 6 h incubation provided a reliable signal window enabling detection of potential inhibitors, the feasibility of the HTS necessitated an overnight incubation. For instance preparation of thirty 384-well plates, our desired goal per day, required approximately 6–7 h of handling prior to the addition of GTP and assay incubation. In addition, BIOMOL Green reagent required a 30 min incubation and each assay plate took approximately 3 min to read on the spectrophotometer (S1 Table). Further, we wanted to avoid preparation of assay plates ahead of time and
subsequent freeze thawing of compound libraries. To mitigate the impractical timeline, we performed a time course, measuring phosphate release following 1, 6, 18, 24, and 36 h of incubation (Fig 1C). We observed that the reaction continued to increase between 6 and 18 hrs. To further compare the two time points, the amounts of released phosphate were tested under multiple incubation conditions: for 6 h at 37°C, 18 h at 37°C, and 18 h at room temperature for comparison, in triplicate 384-well plates which would allow us to obtain preliminary HTS statistical analyses (Fig 1D). Ultimately, 18 h at 37°C was selected because the greatest amplitude of signals between the positive and negative controls was achieved, as demonstrated by the signal window of 4.25, compared to 2.33 and 2.76 for 6 h at 37°C and 18 h at room temperature, respectively.

Our positive control for the assay was reaction mixture lacking Mg2+, because inhibitors of Obg are currently not known. The negative control was the complete reaction in buffer A (as described in Materials and Methods) containing ObgGC, GTP and 10 mM MgCl2. For all tested incubation times, there was a statistically significant difference between the amounts of free phosphate detected in reactions where Mg2+ was present as compared to reactions without Mg2+ (Fig 1C and 1D; blue bars versus red bars).

**Fig 1. Assay optimization.** The concentrations of ObgGC and GTP were selected to achieve an optimal signal window for the HTS assay using as a read-out colorimetric free phosphate quantitation with BIOMOLGreen. (A) Various concentrations of ObgGC (1–10 μM) were incubated with 125 μM GTP for 6 h at 37°C, followed by measurement of free phosphate amounts. (B) ObgGC (5 μM) was incubated with increasing concentrations of GTP (125–1000 μM) for 6 h at 37°C and the free phosphate present in each reaction was quantitated. (C) Time course with 5 μM ObgGC and 250 μM GTP assayed at 0, 1, 6, 18, 24 and 36 h demonstrated that the Obg-dependent GTP hydrolysis continued to increase until approximately 18 h. (D) ObgGC (5 μM) was incubated with GTP (250 μM) in the presence or absence of Mg2+ for 6 or 18 h at either 37°C or room temperature (RT). The signal windows for the three incubation conditions were 2.33, 4.25, and 2.76, respectively, indicating that 18 h incubation time at 37°C was the most optimal. There was no significant difference between free phosphate amounts detected in reactions lacking Mg2+ (red bars) and that of buffer alone (background, white bars). Asterisk denotes significant difference between complete reaction (blue bars) and reaction mixture lacking Mg2+ (ANOVA, P < 0.0001).
The dependence of Obg proteins on Mg\(^{2+}\) to bind GTP has been previously demonstrated, and in GC, the maximal formation of Obg-GTP complexes occurs between 5 and 10 mM Mg\(^{2+}\) [11, 31, 47, 48]. In contrast, binding of GDP by Obg does not require Mg\(^{2+}\), and in fact was inhibited for ObgGC at concentrations above 1 mM [11], suggesting that our assay reaction conditions were conducive to multiple turnover, and our positive control represented an optimally inhibited reaction. In contrast, for GTPases like Ras GAPs, \(G_\alpha\), and GDP/GTP exchange are rate limiting and the enzyme turnover rate is slow. Therefore utilizing a steady-state assay like BIOMOL Green with such proteins becomes a challenge [12, 49, 50].

The kinetic characterization of ObgGC demonstrated a Michaelis-Menten constant (Km) of 78 μM (S3 Fig). Using a concentration of substrate at or less than the Km of the enzyme has been suggested to create conditions sensitive to competitive inhibitors in HTS [43, 45, 51]. However, given the proposed Obg’s intracellular action as a GTP sensor [12], and it’s GTP/GDP binding affinity under different Mg\(^{2+}\) concentrations [11], using a higher concentrations of GTP provided a wider signal window to identify potential inhibitors. The capacity of a HTS to detect an inhibitor depends not only on the biochemical mechanism of action between the enzyme and the substrate, but also the concentration of the inhibitor and the mechanism of action of an inhibitor [52]. Therefore, the concentration of library compounds used in our screen was 40 μM to increase the chance of detecting an inhibitor, regardless of the mechanism (s) of action.

Assessment of ObgGC solvent tolerance and chelator challenge

The inherent range of solubility of chemicals in any screening library necessitates the use of a solvent in biochemical assays. To assess the ObgGC tolerance to the compound solvent, the Obg-GTPase activity was examined using 0, 1, 2, 3, 4, and 5% DMSO during optimized conditions for 18 h at 37°C as described above (Fig 1C). The amount of released phosphate remained similar (~180 μM) under all tested conditions, providing evidence that the GTPase activity of ObgGC was not affected by the presence of solvent to be used in our screen (Fig 2A).

Chelators are often used in biochemistry to sequester metals in reactions, rendering the metals biologically unavailable. Common chelators including EDTA, EGTA, and NTA exhibit varying capacities to bind transition metals such as Ca\(^{2+}\), Mg\(^{2+}\), Fe\(^{2+}\), and Fe\(^{3+}\). The potential for other molecules to exhibit some ability to bind biologically relevant metals, including Mg\(^{2+}\), a critical component of our assay because of its requirement for Obg-GTP interaction, may pose a challenge to our study design, despite that the concentration of Mg\(^{2+}\) in the buffer (10 mM) is in excess of the 40 μM compounds. Therefore, the ability for common chelators to inhibit ObgGC activity under the experimental conditions of the primary screen was assessed. ObgGC was pre-incubated for 1 h with 40 μM of different chelators including EDTA, EGTA, NTA and CA. Only the presence of CA caused a significant decrease in the amount of free phosphate detected, equivalent to less than 20% inhibition (Fig 2B). However, the background phosphate levels for CA (chelator + buffer A + GTP) was 50% lower than that of the other three chelators (data not shown), suggesting that the reduction in signal was due to an interaction with a component of the reagents used, not a \textit{bona fide} inhibition of protein activity.

Together, these studies demonstrated the compatibility of our assay with a high DMSO concentration as well as with a potential chelating agent.

Primary screen for inhibitors of ObgGC

Our assay development efforts afforded primary screening conditions that were both sensitive and practical for HTS. Therefore, ObgGC was screened against 40,000 diverse compounds using the SIGA chemical libraries through OTRADI. These libraries contain an assortment of
both synthetic molecules and natural products, and have been previously used in other HTS [7, 53, 54].

An initial screen of 3,200 compounds (10 plates) was performed, and the calculated Z’ value was 0.55 and a signal window of 4.47, similar to that of our optimization studies (Fig 1C), indicating an excellent assay design [44, 45]. The entire pilot screen took place over five weeks, and the performance of our assay was assessed with standard HTS statistical parameters [44, 45] on each day of the screen (Table 1). The averaged Z’ factor for the entire screen was 0.58 ± 0.02.

The intra- and inter-plate (%CV) variability was also determined for both positive and negative controls. Inter-plate variability was higher for both negative (13.13 ± 1.6%) and positive (13.13 ± 2.9%) controls than the respective intra-plate variabilities (3.58 ± 1.4% and 5.13 ± 1.6%). Variability among the positive controls was on average higher than that of negative controls for both statistical parameters (%C), which may be at least partially due to the fact that there were twice as many positive controls as there were negative controls. Overall, the statistical evaluation of our screen showed a robust assay suitable for HTS of small molecules libraries for identification of potential Obg inhibitors.

**Fig 2. Assessments of solvent tolerance and chelator challenge.** Potential complications of screening conditions were addressed by challenging ObgGC with various concentrations of DMSO (A) or multiple known chelators (B) followed by measurement of GTPase ObgGC activity using free phosphate quantitation with BIOMOL Green. Protein activity was similar in the presence of 0–5% DMSO and in the presence of three common chelators EDTA, EGTA, and NTA tested 40 μM final concentration. CA significantly decreased the amount of phosphate detected, but it also decreased the background phosphate in the reaction lacking ObgGC (not shown), and was therefore altering the absorbance of the reagent, not acting as a chelator. Asterisk denotes significant difference (ANOVA, P < 0.0001).

doi:10.1371/journal.pone.0148222.g002
Our pilot screening campaign revealed 69 compounds exhibiting greater than 15% inhibition of Obg, or less than 85% residual activity, as calculated using Eq 1 explained in the Materials and Methods section. Screening 40,000 compound multiple times to improve assay sensitivity [52] was cost prohibitive. Therefore, for cherry-picking confirmation, molecules with 15% and greater inhibition in the primary screen were retested at 40 μM in triplicate. Ultimately, a hit was defined as a chemical resulting in 50% or less of residual Obg activity compared to the negative control calculated using Eq 1. Two chemicals, named Compound A and Compound B (defined in Materials and Methods), which inhibited Obg GC activity approximately 50% on three replicate plates, were selected for further analysis. Both compounds were ordered from outside vendors, and their ability to inhibit ObgGC was tested at 40 and 100 μM, alongside the EngA inhibitor, Garcinol, identified in [43]. To eliminate the possibility that these compounds were false positives, the signal produced by 40 μM phosphate in the presence of 40 and 100 μM compound was also measured. Neither of the lead compounds demonstrated any significant inhibition of the protein, despite having a 50% inhibition in three replicate plates of the follow-up screen (S2B and S2C Fig).

The low hit rate following our primary screen, and lack of confirmed lead compound, is not uncommon for a pilot screen of only 40,000. In other HTS studies, > 85% of the initial hits were found to be non-specific for the target molecule [43, 53, 54]. Screening a greater number of small molecules will increase the chance of identifying candidates for further development. Ultimately, two inhibitors were identified through our screen, which demonstrates that the assay is working. The failure of confirmation testing of the initial hits using purchased chemicals is not a reflection on the assay, but may suggest that their anti-Obg activity originated from a degradation product(s) and/or impurities of the parent compound sample in the library. There is a wide range of rearrangements and chemical reactions (e.g. oxidation, hydrolysis, isomerization) that may occur in a structurally diversified collection of compounds upon storage in DMSO solution [55]. Other factors such as compound concentration, intrinsic stability, presence of reactive contaminants, and storage related factors (e.g. type of containers, storage conditions, time of storage) could affect compound stability [56].

### Secondary screen for elucidating mechanism of ObgGC inhibition

A secondary assay was developed as a follow up study for lead compounds in order to not only confirm their ability to inhibit Obg hydrolysis, but also to elucidate a possible mechanism of...
compound action. When fluorescent guanine nucleotide analogs, mant-GTP and mant-GDP, are bound to Obg GC, there is 1.9- and 1.3-fold increase in fluorescence, respectively [11], which is similar to values reported for other bacterial Obg proteins [31, 47, 48]. Overall, this assay is useful because it delivers a different read-out method with the sensitivity inherent to a fluorescence assay (compared with the colorimetric reaction used in the primary screening) and provides a means to dissect the interaction(s) that may occur between a compound, Obg, and mant-nucleotides.

In addition to the positive control of reaction mixture lacking Mg\(^2+\), used in the primary screen assay, an alternative positive control was developed for the secondary assay. An Obg variant, °ObgGC, was designed with multiple mutations within the G domain, at T192S, T193S, A212L, D213E, P215H, N284Q, K285R, S329V within G domains (outlined in detail in S1 Fig). °ObgGC activity in the mant-GTP assay was not significantly different from that of ObgGC in the absence of Mg\(^2+\). Asterisk denotes significant difference (ANOVA, \(P < 0.0001\)).

Assessment of broad-spectrum potential of Obg inhibitors

The ability of potential lead compounds to act on other clinically relevant bacteria by targeting Obg could be further assessed by utilizing Obg homologs from bacterial species associated with...
serious antibiotic resistant infections for instance *K. pneumoniae* and MRSA [57–59]. *K. pneumoniae* is a Gram-negative bacterium and an opportunistic pathogen, which causes, in addition to pneumonia, infections in the urinary tract, wound or surgical sites, blood stream, and meningitis. It is one of the top organisms causing infections in hospitalized patients [57, 59]. Particularly vulnerable to *K. pneumoniae* infections are immunocompromised individuals, in which the disease can result in death. *K. pneumoniae* is one of the two most common carbapenem-resistant *Enterobacteriaceae*, and is listed by the CDC as an urgent threat as a result of its prevalence and resistance to antibiotics [2]. MRSA is a Gram-positive bacterium, which causes a range of illnesses, from skin and wound infections to sepsis, and it constitutes approximately 28% of hospital-acquired bacterial pneumonia [58, 59]. The number of MRSA infections is among the highest of all antibiotic-resistant diagnoses, and it is therefore listed as a serious threat by the CDC [2]. Presently, there are effective antibiotics capable of treating MRSA-derived infections. However, the prevalence and persistence of such infections may facilitate the resilience of more resistant strains of MRSA, generating a greater need for novel treatments [2]. Together with *N. gonorrhoeae*, they represent a diverse set of clinically important bacteria that are all in need of novel and aggressive antibiotic development.

The Obg proteins of *K. pneumoniae*, ObgKP, and MRSA, ObgMRSA, were cloned, expressed in *E. coli* and purified, followed by characterization of their biochemical activities in colorimetric and fluorescent assays under the same conditions described for ObgGC (Fig 4). All three proteins exhibited similar GTPase activity in the BIOMOL Green assay, producing ~120, 140, and 130 µM phosphate for ObgGC, ObgKP, and ObgMRSA, respectively, with 5 µM protein and 250 µM GTP in each reaction at the end of the 18 h incubation (Fig 4A). Like ObgGC, ObgKP and ObgMRSA, hydrolyzed GTP only in the presence of Mg<sup>2+</sup>. ObgKP also behaved similar to other Obg homologs [11, 31, 47, 48] in the fluorescence-based assay, as binding of mant-GTP and mant-GDP resulted in ~1.8- and 1.3-fold increase in fluorescence, respectively (Fig 4B). In contrast, complexes of ObgMRSA-mant-GTP and ObgMRSA-mant-GDP showed ~1.4- and 1.1-fold elevation in relative fluorescence, respectively (Fig 4B). There was, however, no significant difference in the amount of free phosphate detected using the BIOMOL Green assay at the end of 18 h incubation with ObgKP and ObgMRSA (ANOVA, P = 0.3109), suggesting that the ObgMRSA may not bind mant-nucleotides as readily as other Obg homologs.

Another useful parameter to further characterize the mechanism of action of a lead compound molecule is the assessment of the GTP hydrolysis rate of Obg proteins. Therefore, we next examined the GTPase activity of the ObgKP and ObgMRSA by monitoring the decrease in fluorescence that is associated with the single-turnover conversion of bound mant-GTP to bound mant-GDP. The reduction in fluorescence was fitted with a single exponential decay equation, and first-order rate constants, $k_{\text{h}}$, $4.64 \times 10^{-4}$ s<sup>−1</sup> and $6.36 \times 10^{-4}$ s<sup>−1</sup>, as well as half-lives (T<sub>1/2</sub>) of 24.88 min and 18.17 min, were determined for ObgKP and ObgMRSA, respectively. The hydrolysis rate of both proteins were similar to Obg from *C. crescentus*, approximately 2-fold faster than *N. gonorrhoeae* and *E. coli*, and 11 and 8-fold slower than *V. harveyi*, respectively [11, 31, 47, 48]. The slight variations in the binding and hydrolysis activities of the Obg homologues may reflect species-specific subtle differences in Obg functions. Nevertheless, combining both the colorimetric and fluorescent assays provide powerful tools for elucidating Obg inhibitors.

**Conclusions**

Obg protein appears to be an excellent target for the development of novel antimicrobials because of its essential nature to both Gram-positive and Gram-negative bacteria. Accordingly,
we have optimized an inexpensive, statistically sound, high-throughput assay to screen for inhibitors of ObgGC. Further, we have developed a secondary method to evaluate the ability of potential lead compounds to interfere with Obg-nucleotide binding and dissect a potential mechanism of action. Finally, we propose to employ Obg homologs from other clinically important and very different bacterial species, *K. pneumoniae* and MRSA, to test the potential for broad-spectrum antibiotic development in targeting Obg.

The screening approach described here will be useful in identifying inhibitors of a ribosome-associated protein with a proposed role in bacterial multidrug tolerance that will further the advancement of broad-spectrum therapeutics, thus meeting the needs raised by CDC and WHO.
Supporting Information

S1 Fig. Schematic outline of Obg<sub>GC</sub> architecture with introduced mutations. The individual domains of Obg<sub>GC</sub> are labeled in dark blue. The central, GTP-binding domain includes switch I and switch II and five conserved G motifs (G1-G5; indicated in blue boxes). The introduced substitutions within the G motifs are designated in red.

S2 Fig. Evaluation of inhibitory potential of GTPase EngA inhibitor, Garcinol, and potential lead compounds identified in a pilot Obg<sub>GC</sub> screen, A & B, using the Biomol® Green assay. Obg<sub>GC</sub> (5 μM) was pre-incubated with tested compounds (40 and 100 μM) followed by the addition of GTP (250 μM), incubation 18 h at 37°C and free phosphate measurement.

S3 Fig. Kinetic characterization of Obg<sub>GC</sub>. The Km of Obg<sub>GC</sub> was determined using 5 μM Obg<sub>GC</sub> and a range of GTP from 10–1000 μM over 6 h. The Km for Obg<sub>GC</sub> was determined to be 78.76 μM.

S1 Table. Timeline of the Obg<sub>GC</sub> HTS procedures.

Acknowledgments
We are grateful to Heather Louderback and Robert Allen from OTRADI for assistance with the primary screen. We are thankful to Benjamin I. Baarda for the initial purification and characterization of Obg<sub>GC</sub>.

Author Contributions
Conceived and designed the experiments: AES KVK. Performed the experiments: JAB RAZ. Analyzed the data: JAB RAZ KVK AES. Contributed reagents/materials/analysis tools: JAB RAZ KVK AES. Wrote the paper: JAB AES.

References
1. Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Ther Adv Drug Saf. 2014; 5(6):229–41. doi: 10.1177/2042098614554919 PMID: 25436105; PubMed Central PMCID: PMC4232501.
2. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, US Department of Health and Human Services. 2013.
3. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis. 2003; 36(11):1433–7. doi: 10.1086/375081 PMID: 12766839.
4. World Health Organization. Antimicrobial resistance draft global action plan on antimicrobial resistance. Geneva; 2015.
5. Coates A, Hu Y, Bax R, Page C. The future challenges facing the development of new antimicrobial drugs. Nat Rev Drug Discov. 2002; 1(11):895–910. doi: 10.1038/nrd940 PMID: 12415249.
6. Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev. 2011; 24(1):71–109. doi: 10.1128/CMR.00030-10 PMID: 21239508; PubMed Central PMCID: PMC3021209.
7. Bolken TC, Hruby DE. Discovery and development of antiviral drugs for biodefense: experience of a small biotechnology company. Antiviral Res. 2008; 77(1):1–5. doi: 10.1016/j.antiviral.2007.07.003 PMID: 17765333; PubMed Central PMCID: PMC2972676.
8. Arias CA, Murray BE. A new antibiotic and the evolution of resistance. N Engl J Med. 2015; 372(12):1168–70. doi: 10.1056/NEJMcb15000292 PMID: 25785976; PubMed Central PMCID: PMC4433155.
9. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nature reviews Drug discovery. 2007; 6(1):29–40. doi: 10.1038/nrd2201 PMID: 17159923.

10. Wilson DN. Ribosome-targeting antibiotics and mechanisms of bacterial resistance. Nat Rev Micro. 2014; 12(1):35–48. doi: 10.1038/nrmicro3155

11. Zielke RA, Wierzbiicki IH, Baarda BI, Sikora AE. The Neisseria gonorrhoeae Obg protein is an essential ribosome-associated GTPase and a potential drug target. BMC Microbiol. 2015; 15(1):129. doi: 10.1186/s12866-015-0453-1 PMID: 26122105.

12. Kint C, Verstraeten N, Hofkens J, Fauvart M, Michiels J. Bacterial Obg proteins: GTPases at the nexus of protein and DNA synthesis. Critical reviews in microbiology. 2014; 40(3):207–24. doi: 10.3109/1040841X.2013.776510 PMID: 23537324.

13. Verstraeten N, Fauvart M, Veresees W, Michiels J. The universally conserved prokaryotic GTPases. Microbiol Mol Biol Rev. 2011; 75(3):507–42. second and third pages of table of contents. doi: 10.1128/MMBR.00009-11 PMID: 20830302; PubMed Central PMCID: PMC2935376.

14. Lin B, Maddock JR. The Caulobacter crescentus CgtAC protein cosediments with the free 50S ribosomal subunit. J Bacteriol. 2004; 186(2):481–9. PMID: 14702318; PubMed Central PMCID: PMC305748.

15. Blombach F, Brouns SJ, van der Oost J. Assembling the archaeal ribosome: roles for translation-factor-related GTPases. Biochem Soc Trans. 2011; 39(1):45–50. doi: 10.1042/BST0390045 PMID: 21265745.

16. Buglino J, Shen V, Hakimian P, Lima CD. Structural and biochemical analysis of the Obg GTP binding protein. Structure. 2002; 10(11):1581–92. PMID: 12429099.

17. Lee Y, Bang WY, Kim S, Lazar P, Kim CW, Bahk JD, et al. Molecular modeling study for interaction between Bacillus subtilis Obg and Nucleotides. PLoS One. 2010; 5(9):e12597. doi: 10.1371/journal.pone.0012597 PMID: 20844575; PubMed Central PMCID: PMC4028186.

18. Kukimoto-Niino M, Murayama K, Inoue M, Terada T, Tame JR, Kuramitsu S, et al. Crystal structure of the GTP-binding protein Obg from Thermus thermophilus HB8. J Mol Biol. 2004; 337(3):761–70. doi: 10.1016/j.jmb.2004.01.047 PMID: 15019792.

19. Lin B, Maddock JR. The N-terminal domain of the Caulobacter crescentus CgtA protein does not function as a guanine nucleotide exchange factor. FEBS Lett. 2001; 489(1):108–11. PMID: 11231024.

20. Jiang M, Datta K, Walker A, Strahler J, Bagamasbad P, Andrews PC, et al. The Escherichia coli GTPase CgtAE is involved in late steps of large ribosome assembly. J Bacteriol. 2006; 188(19):6757–70. doi: 10.1128/JB.188.19.6757–70 PMID: 16980477; PubMed Central PMCID: PMC1595513.

21. Feng B, Mandava CS, Guo Q, Wang J, Cao W, Li N, et al. Structural and functional insights into the mode of action of a universally conserved Obg GTPase. PLoS biology. 2014; 12(5):e1001866. doi: 10.1371/journal.pbio.1001866 PMID: 24844575; PubMed Central PMCID: PMC4028186.

22. Geyer M, Wittinghofer A. GEFs, GAPs, GDIs and effectors: taking a closer (3D) look at the regulation of Ras-related GTP-binding proteins. Curr Opin Struct Biol. 1997; 7(6):786–92. PMID: 9434896.

23. Trach K, Hoch JA. The Bacillus subtilis spo0B stage 0 sporulation operon encodes an essential GTP-binding protein. J Bacteriol. 1989; 171(3):1362–71. PMID: 2537815; PubMed Central PMCID: PMC209754.

24. Okamoto S, Ochi K. An essential GTP-binding protein functions as a regulator for differentiation in Streptomyces coelicolor. Mol Microbiol. 1998; 30(1):107–19. PMID: 9786189.

25. Zalacain M, Biswas SA, Ingraham KA, Ambrad J, Bryant A, Chalker AF, et al. A global approach to identify novel broad-spectrum antibacterial targets among proteins of unknown function. J Mol Microbiol Biotechnol. 2003; 6(2):109–17. doi: 10.1080/1040841X.2013.776510 PMID: 23537324.

26. Maddock J, Bhatt A, Koch M, Skidmore J. Identification of an essential Caulobacter crescentus cgtA gene encoding a member of the Obg family of GTP-binding proteins. J Bacteriol. 1997; 179(20):6426–31. PMID: 9335292; PubMed Central PMCID: PMC1795513.

27. Arigoni F, Talabot F, Peitsch M, Edgerton MD, Meldrum E, Allet E, et al. A genome-based approach for the identification of essential bacterial genes. Nature biotechnology. 1998; 16(9):851–6. doi: 10.1038/ nb0998-851 PMID: 9743119.

28. Sikora AE, Zielke R, Datta K, Maddock JR. The Vibrio harveyi GTPase CgtAV is essential and is associated with the 50S ribosomal subunit. J Bacteriol. 2006; 188(3):1205–10. doi: 10.1128/JB.188.3.1205–1210.2006 PMID: 16428430; PubMed Central PMCID: PMC1347350.

29. Shah S, Das B, Bhadra RK. Functional analysis of the essential GTP-binding-protein-coding gene cgtA of Vibrio cholerae. J Bacteriol. 2008; 190(13):4764–71. doi: 10.1128/JB.02021-07 PMID: 18456812; PubMed Central PMCID: PMC2446790.
30. Verstraeten N, Knapen WJ, Kint CI, Liebens V, Van den Bergh B, Dewachter L, et al. Obg and Membrane Depolarization Are Part of a Microbial Bet-Hedging Strategy that Leads to Antibiotic Tolerance. Mol Cell. 2015; 59(1):9–21. doi:10.1016/j.molcel.2015.05.011 PMID: 26051177.

31. Lin B, Covalle KL, Maddock JR. The Caulobacter crescentus CgtA protein displays unusual guanine nucleotide binding and exchange properties. J Bacteriol. 1999; 181(18):5825–32. PMID: 10482526; PubMed Central PMCID: PMC94105.

32. Walsh KM, Trach KA, Folger C, Hoch JA. Biochemical characterization of the essential GTP-binding protein Obg of Bacillus subtilis. J Bacteriol. 1994; 176(23):7161–8. PMID: 7961487; PubMed Central PMCID: PMC197103.

33. Tenson T, Mankin A. Antibiotics and the ribosome. Mol Microbiol. 2006; 59(6):1664–77. doi:10.1111/j.1365-2958.2006.05063.x PMID: 16553874.

34. CDC. Antibiotic / Antimicrobial Resistance 2013 [updated September 16, 2013; cited July 19, 2010 July 9, 2015]. Available from: http://www.cdc.gov/drugresistance/biggest_threats.html.

35. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, et al. Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting. PLoS One. 2015; 10(12):e0143304. doi:10.1371/journal.pone.0143304 PMID: 26646541.

36. World Health Organization. Global action plan to control the spread and impact of antimicrobial resistance 2015-2019. 2014; p. 232. Available from: http://whqlibdoc.who.int/publications/2015/9789241503501_eng.pdf.

37. Edwards JL, Apicella MA. The molecular mechanisms used by Neisseria gonorrhoeae to initiate infection differ between men and women. Clin Microbiol Rev. 2004; 17(4):961–61, table of contents. Epub 2004/10/19. 17/4/961 [pii] doi:10.1128/CMR.17.4.965–981.2004 PMID: 15489357; PubMed Central PMCID: PMC523569.

38. Unemo M. Challenges with antimicrobial susceptibility testing for Neisseria gonorrhoeae in the era of extensively drug-resistant gonorrhoea—molecular antimicrobial resistance testing crucial. Pathogens and global health. 2014; 108(5):214–20. doi:10.1119/1087057113486001 PMID: 25175873; PubMed Central PMCID: PMC4153821.

39. Unemo M. Current and future antimicrobial treatment of gonorrhoea—the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infect Dis. 2015; 15:364. doi:10.1186/s12879-015-1029-2 PMID: 26293005; PubMed Central PMCID: PMC4546108.

40. World Health Organization. Antimicrobial resistance: global report on surveillance. Geneva: World Health Organization; 2014. p. 232.

41. Centers for Disease Control and Prevention. Grand Rounds: The Growing Threat of Multidrug-Resistant Gonorrhea. MMWR Morb Mortal Wkly Rep. 2013; 62:103–6. Epub 2013/02/15. PMID: 23407126.

42. Itaya K, Ui M. A new micromethod for the colorimetric determination of inorganic phosphate. Clin Chim Acta. 1966; 14(3):361–6. doi:10.1016/0009-8981(66)90114-8 PMID: 5970965.

43. Bharat A, Blanchard JE, Brown ED. A high-throughput screen of the GTPase activity of CgtA to find an inhibitor of bacterial ribosome biogenesis. J Biomol Screen. 2013; 18(7):830–5. doi:10.1177/1087057113486001 PMID: 23606650; PubMed Central PMCID: PMC4061131.

44. Zhang JH, Chung TDY, Oldenburg KR. A simple statistical parameter for use in validation of high throughput screening assays. Journal of biomolecular screening. 1999; 4(2):67–73. doi:10.1177/108705719900400206 PMID: WOS:000082230000005.

45. Inglese J, Johnson RL, Simeonov A, Xia M, Zheng W, Austin CP, et al. High-throughput screening assays for the identification of chemical probes. Nature chemical biology. 2007; 3(8):466–79. doi:10.1038/nchembio.2007.17 PMID: 17637779.

46. Lin B, Skidmore JM, Bhatt A, Pfeffer SM, Pawloski L, Maddock JR. Alanine scan mutagenesis of the switch I domain of the Caulobacter crescentus CgtA protein reveals critical amino acids required for in vivo function. Mol Microbiol. 2001; 39(4):924–34. PMID: 11251813.

47. Wout P, Pu K, Sullivan SM, Reese V, Zhou S, Lin B, et al. The Escherichia coli GTPase CgtAE cofractionates with the 50S ribosomal subunit and interacts with SpoT, a ppGpp synthetase/hydrolase. J Bacteriol. 2004; 186(16):5249–57. doi:10.1128/JB.186.16.5249–5257.2004 PMID: 15292126; PubMed Central PMCID: PMC490892.

48. Sikora AE, Datta K, Maddock JR. Biochemical properties of the Vibrio harveyi CgtAV GTPase. Biochem Biophys Res Commun. 2006; 339(4):1165–70. doi:10.1016/j.bbrc.2005.11.129 PMID: 16343434.

49. Schrotter G, Mann D, Kotting C, Gerwert K. Integration of Fourier Transform Infrared Spectroscopy, Fluorescence Spectroscopy, Steady-state Kinetics and Molecular Dynamics Simulations of GalphaI Distinguishes between the GTP Hydrolysis and GDP Release Mechanism. J Biol Chem. 2015; 290.
50. Monroy CA, Mackie DI, Roman DL. A high throughput screen for RGS proteins using steady state monitoring of free phosphate formation. PLoS One. 2013; 8(4):e62247. doi:10.1371/journal.pone.0062247 PMID: 23626793; PubMed Central PMCID: PMC3633906.

51. Copeland RA. Mechanistic considerations in high-throughput screening. Analytical biochemistry. 2003; 320(1):1–12. doi:10.1016/s0003-2697(03)00346-4 PMID: 12895464

52. Buxser S, Vroegop S. Calculating the probability of detection for inhibitors in enzymatic or binding reactions in high-throughput screening. Anal Biochem. 2005; 340(1):1–13. doi:10.1016/j.ab.2005.01.034 PMID: 15802124.

53. Sandoz KM, Eriksen SG, Jeffrey BM, Suchland RJ, Hruby DE, et al. Resistance to a novel antichlamydial compound is mediated through mutations in Chlamydia trachomatis secY. Antimicrob Agents Chemother. 2012; 56(8):4296–302. Epub 2012/05/31. doi:10.1128/AAC.00356-12 PMID: 22644029; PubMed Central PMCID: PMC3421553.

54. Larson RA, Dai D, Hosack VT, Tan Y, Bokken TC, Hruby DE, et al. Identification of a broad-spectrum arenavirus entry inhibitor. J Virol. 2008; 82(21):10768–75. doi:10.1128/JVI.00941-08 PMID: 18715909; PubMed Central PMCID: PMC2573164.

55. Zitha-Bovens E, Maas P, Wife D, Tijhuis J, Hu QN, Kleinoder T, et al. COMDECOM: predicting the lifetime of screening compounds in DMSO solution. Journal of biomolecular screening. 2009; 14(5):557–65. doi:10.1177/1087057109336953 PMID: 19483143.

56. Blaxill Z, Holland-Crimmin S, Lifely R. Stability through the ages: the GSK experience. Journal of biomolecular screening. 2009; 14(5):547–56. doi:10.1177/1087057109335327 PMID: 19470717.

57. Pitout JD, Nordmann P, Poirel L. Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance. Antimicrob Agents Chemother. 2015; 59(10):5873–84. doi: 10.1128/AAC.01019-15 PMID: 26169401; PubMed Central PMCID: PMC4576115.

58. Holmes NE, Tong SY, Davis JS, Hal SJ. Treatment of methicillin-resistant Staphylococcus aureus: vancomycin and beyond. Semin Respir Crit Care Med. 2015; 36(1):17–30. doi: 10.1055/s-0034-1397040 PMID: 25643268.

59. Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis. 2010; 51 Suppl 1:S81–7. doi: 10.1086/653053 PMID: 20597676.